<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.102.3" />


<title>Publications - Keaven M. Anderson</title>
<meta property="og:title" content="Publications - Keaven M. Anderson">


  <link href='/favicon.ico' rel='icon' type='image/x-icon'/>



  







<link rel="stylesheet" href="/css/fonts.css" media="all">
<link rel="stylesheet" href="/css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="/" class="nav-logo">
    <img src="/images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="/publications/">Publications</a></li>
    
    <li><a href="/software/">Software</a></li>
    
    <li><a href="/talks/">Talks</a></li>
    
    <li><a href="https://github.com/keaven">GitHub</a></li>
    
    <li><a href="https://www.linkedin.com/in/keaven-anderson-09aa7538/">LinkedIn</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    

    <h1 class="article-title">Publications</h1>

    

    <div class="article-content">
      <p>(Under construction)</p>
<h2 id="recent">Recent</h2>
<p>Mukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., &amp; Chappell, R. J. (2022). Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. JAMA oncology.</p>
<p>Anderson, K. M., Guo, Z., Zhao, J., &amp; Sun, L. Z. (2022). A unified framework for weighted parametric group sequential design. Biometrical Journal.</p>
<p>Chen, T. Y., Zhao, J., Sun, L., &amp; Anderson, K. M. (2021). Multiplicity for a group sequential trial with biomarker subpopulations. Contemporary Clinical Trials, 101, 106249.</p>
<p>Bautista, O., &amp; Anderson, K. (2021). Sample Size Estimation and Power Analysis: Time to Event Data. In Handbook of Statistical Methods for Randomized Controlled Trials (pp. 275-300). Chapman and Hall/CRC.</p>
<p>Roychoudhury, S., Anderson, K. M., Ye, J., &amp; Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with nonproportional hazards: a straw man guidance from a cross-pharma working group. Statistics in Biopharmaceutical Research, 1-15.</p>
<p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., &hellip; &amp; Working, C. P. N. P. H. (2020). Rejoinder to letter to the editor “The hazards of period specific and weighted hazard ratios”. Statistics in Biopharmaceutical Research, 12(4), 520.</p>
<p>Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., &hellip; &amp; Cross-Pharma Non-Proportional Hazards Working Group. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Statistics in Biopharmaceutical Research, 12(2), 187-198.</p>
<p>Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., &amp; Wei, L. J. (2020). On the empirical choice of the time window for restricted mean survival time. Biometrics, 76(4), 1157-1166.</p>
<p>León, L. F., Lin, R., &amp; Anderson, K. M. (2020). On weighted log-rank combination tests and companion Cox model estimators. Statistics in Biosciences, 12(2), 225-245.</p>
<p>Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., &hellip; &amp; Stone, J. A. (2018). Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic ClearancePembrolizumab PK/PD Confounding and Cancer Cachexia. Clinical Cancer Research, 24(23), 5841-5849.</p>
<p>Joseph, Richard W., et al. &ldquo;Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab: Impact of Baseline Tumor Size on Outcomes in Melanoma.&rdquo; <em>Clinical Cancer Research</em> <em>24.20</em> (2018): 4960-4967.</p>
<p>Chen, Cong, et al. &ldquo;A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.&rdquo; Contemporary clinical trials 64 (2018): 238-242.</p>
<h2 id="1999">1999</h2>
<ul>
<li>Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H.,
Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I.,
Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and
extent of thrombolysis: Results of the thrombolysis in myocardial
infarction (TIMI) 14 trial. <em>Circulation</em>, <em>99</em>(21), 2720–2732.</li>
</ul>
<h2 id="1997">1997</h2>
<ul>
<li>
<p>CAPTURE Investigators and others. (1997). Randomized
placebo-controlled trial of abciximab before and during coronary
intervention in refractory angina: The CAPTURE study. <em>Lancet</em>, <em>349</em>,
1429–1435.</p>
</li>
<li>
<p>EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa
receptor blockade and low-dose heparin during percutaneous coronary
revascularization. <em>New England Journal of Medicine</em>, <em>336</em>(24),
1689–1697.</p>
</li>
<li>
<p>Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis,
S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P.,
Anderson, K. M., et al. (1997). Long-term protection from myocardial
ischemic events in a randomized trial of brief integrin <em>β</em>3
blockade with percutaneous coronary intervention. <em>JAMA</em>, <em>278</em>(6),
479–484.</p>
</li>
</ul>
<h2 id="1994">1994</h2>
<ul>
<li>
<p>EPIC Investigators. (1994). Use of a monoclonal antibody directed
against the platelet glycoprotein IIb/IIIa receptor in high-risk
coronary angioplasty. <em>New England Journal of Medicine</em>, <em>330</em>(14),
956–961.</p>
</li>
<li>
<p>Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley,
S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994).
Randomised trial of coronary intervention with antibody against platelet
IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six
months. <em>The Lancet</em>, <em>343</em>(8902), 881–886.</p>
</li>
</ul>
<h2 id="1993">1993</h2>
<ul>
<li>Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., &amp; Levy, D.
(1993). Survival after the onset of congestive heart failure in
framingham heart study subjects. <em>Circulation</em>, <em>88</em>(1), 107–115.</li>
</ul>
<h2 id="1992">1992</h2>
<ul>
<li>Castelli, W. P., Anderson, K., Wilson, P. W., &amp; Levy, D. (1992).
Lipids and risk of coronary heart disease the framingham study. <em>Annals
of Epidemiology</em>, <em>2</em>(1-2), 23–28.</li>
</ul>
<h2 id="1991">1991</h2>
<ul>
<li>
<p>Anderson, K. M., Odell, P. M., Wilson, P. W., &amp; Kannel, W. B.
(1991). Cardiovascular disease risk profiles. <em>American Heart Journal</em>,
<em>121</em>(1), 293–298.</p>
</li>
<li>
<p>Anderson, K. M., Wilson, P., Odell, P. M., &amp; Kannel, W. B. (1991).
An updated coronary risk profile. A statement for health professionals.
<em>Circulation</em>, <em>83</em>(1), 356–362.</p>
</li>
<li>
<p>Galderisi, M., Anderson, K. M., Wilson, P. W., &amp; Levy, D. (1991).
Echocardiographic evidence for the existence of a distinct diabetic
cardiomyopathy (the framingham heart study). <em>The American Journal of
Cardiology</em>, <em>68</em>(1), 85–89.</p>
</li>
<li>
<p>Lauer, M. S., Anderson, K. M., Kannel, W. B., &amp; Levy, D. (1991).
The impact of obesity on left ventricular mass and geometry: The
framingham heart study. <em>JAMA</em>, <em>266</em>(2), 231–236.</p>
</li>
</ul>
<h2 id="1990">1990</h2>
<ul>
<li>
<p>D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A.,
Anderson, K., &amp; Kannel, W. B. (1990). Relation of pooled logistic
regression to time dependent cox regression analysis: The framingham
heart study. <em>Statistics in Medicine</em>, <em>9</em>(12), 1501–1515.</p>
</li>
<li>
<p>Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C.,
Kannel, W. B., &amp; Castelli, W. P. (1990). Determinants of sensitivity and
specificity of electrocardiographic criteria for left ventricular
hypertrophy. <em>Circulation</em>, <em>81</em>(3), 815–820.</p>
</li>
<li>
<p>Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., &amp;
Castelli, W. P. (1990). Prognostic implications of echocardiographically
determined left ventricular mass in the framingham heart study. <em>New
England Journal of Medicine</em>, <em>322</em>(22), 1561–1566.</p>
</li>
</ul>
<h2 id="1988">1988</h2>
<ul>
<li>LEVY, D., ANDERSON, K. M., SAVAGE, D. D., KANNEL, W. B.,
CHRISTIANSEN, J. C., &amp; Castelli, W. P. (1988). Echocardiographically
detected left ventricular hypertrophy: Prevalence and risk factors: The
framingham heart study. <em>Annals of Internal Medicine</em>, <em>108</em>(1), 7–13.</li>
</ul>
<h2 id="1987">1987</h2>
<ul>
<li>
<p>Anderson, K. M., Castelli, W. P., &amp; Levy, D. (1987). Cholesterol
and mortality: 30 years of follow-up from the framingham study. <em>JAMA</em>,
<em>257</em>(16), 2176–2180.</p>
</li>
<li>
<p>Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel,
W. B., &amp; Castelli, W. P. (1987). Echocardiographic criteria for left
ventricular hypertrophy: The framingham heart study. <em>The American
Journal of Cardiology</em>, <em>59</em>(9), 956–960.</p>
</li>
<li>
<p>Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W.
B., &amp; Castelli, W. P. (1987). Risk of ventricular arrhythmias in left
ventricular hypertrophy: The framingham heart study. <em>The American
Journal of Cardiology</em>, <em>60</em>(7), 560–565.</p>
</li>
</ul>
<h2 id="1986">1986</h2>
<ul>
<li>Castelli, W. P., &amp; Anderson, K. (1986). A population at risk:
Prevalence of high cholesterol levels in hypertensive patients in the
framingham study. <em>The American Journal of Medicine</em>, <em>80</em>(2), 23–32.</li>
</ul>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="/index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
        </ul>
      </footer>

    </div>
    

    

    
  </body>
</html>

